Clinical Study
Dual PPAR α/γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia
Table 4
Plasma concentrations of lipoprotein subclasses (mg/dL) in patients with chronic renal insufficiency (n = 23) and healthy reference subjects (n = 17) at start and end of treatment with 1 mg tesaglitazar o.d. Mean and standard (in parenthesis).
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P < 0.05, **P < 0.01, and ***P < 0.001 with group comparison between baseline and after 6 weeks of treatment. |